Healthcare Frost Radar in the Immunoassay and Clinical Chemistry Market

A Measurement System to Spark Companies 2 Action (C2A)—Innovation That Fuels New Deal Flow and Growth Pipelines

INDUSTRY
Healthcare
SECTOR
Life Sciences

RELEASE DATE
23-Sep-2019
REGION
North America
DELIVERABLE TYPE
Frost Radar

RESEARCH CODE
K3F6-01-00-00-00
SKU
HC03215-GL-MR_23585
Yes
SHARE

Frost Radar in the Immunoassay and Clinical Chemistry Market
Published on: 23-Sep-2019 | SKU: HC03215-GL-MR_23585

Need more details?

$4,950.00

$3,712.50 save 25 %

DownloadLink
Need more details?

The immunoassay and clinical chemistry market is the highest share contributor for the total in vitro diagnostics (IVD) market. Globally valued at $28.7 billion in 2019, this market segment contributes 37.6% of the total IVD market of $76.3 billion. Within the high-medium to low analyzer segment, there are over 40 companies globally. Of these, 14 companies are benchmarked in this study. Point of care testing is not included in this study.

The market concentration is relatively high amidst the Tier I companies, which includes Siemens Healthineers, Roche Diagnostics, Abbott Diagnostics, Beckman Coulter, and Ortho Clinical Diagnostics. Some evolving trends include an interest in small scale analyzers and niche/specialty reagents. There is also a need to establish references that generate a push to single-vendor system across a healthcare system. There is heavy focus on automation to address sample management, especially in pediatric hospitals, and there is an interest in adding third-party niche assays to existing platforms.

Finally, there is a need for constant research and development (R&D) innovation to add a new pipeline of assays in areas such as brain injury, hs- troponin (particularly in the United States), sepsis, and other potential applications of PCT, ischemic stroke, and kidney disease.

The report provides global market share, market size, and brand penetration and pricing/discounts on popular vendors and models from FY 2018 to FY 2019.

The companies that are profiled in this report include Roche Diagnostics, Siemens Healthineers, Abbott Diagnostics, Beckman Coulter (Danaher), Ortho Clinical Diagnostics, Bio-Rad, Thermo Fisher Scientific, bioMerieux, Fujirebio, Sekisui Diagnostics, MindRay, Randox, and Sysmex. The report provides a summary of the strengths, opportunity areas, and position of these companies on the Frost Radar across the growth index and innovation index. Particular R&D activities and installed bases on analyzers and strategic expansion plans have been noted.

The Frost Radar reveals the market positioning of companies in an industry using their Growth and Innovation scores as highlighted in the Frost Radar methodology. The document presents competitive profiles on each of the companies in the Frost Radar based on their strengths, opportunities, and a small discussion on their positioning. Frost & Sullivan analyzes hundreds of companies in the industry and benchmarks them across 10 criteria on the Frost Radar, where the leading companies in the industry are then positioned. Industry leaders on both the Growth and Innovation indices are recognized as best practice recipients.

Author: Divyaa Ravishankar

Industry Overview

Industry Overview (continued)

Industry Overview (continued)

Popular Vendors and Models

Pricing and Installed Base

Global Market Share Analysis

The Frost Radar

Frost Radar—Description of Companies Plotted

Roche Diagnostics

Siemens Healthineers

Abbott Diagnostics

Ortho Clinical Diagnostics

Beckman Coulter (Danaher)

Fujirebio

Randox Laboratories

Mindray

bioMérieux

Tosoh Bioscience

Bio-Rad

Sysmex

Thermo Fisher Scientific

Sekisui Diagnostics

The Last Word—Key Takeaways

Legal Disclaimer

Frost Radar—2 Major Indices, 10 Analytical Ingredients, 1 Platform

Frost Radar—2 Major Indices, 10 Analytical Ingredients, 1 Platform (continued)

Frost Radar—C2A

Frost Radar™: Benchmarking Future Growth Potential 2 Major Indices, 10 Analytical Ingredients, 1 Platform

Growth Index

Growth Index (GI) is a measure of a company’s growth performance and track record, along with its ability to develop and execute a fully aligned growth strategy and vision; a robust growth pipeline system; and effective market, competitor, and end-user focused sales and marketing strategies.

  • Market Share (previous 3 years)
    This is a comparison of a company’s market share relative to its competitors in a given market space for the previous 3 years.
  • Revenue Growth (previous 3 years)
    This is a look at a company’s revenue growth rate for the previous 3 years in the market/industry/category that forms the context for the given Frost Radar™.
  • Growth Pipeline
    This is an evaluation of the strength and leverage of a company’s growth pipeline system to continuously capture, analyze, and prioritize its universe of growth opportunities.
  • Vision and Strategy
    This is an assessment of how well a company’s growth strategy is aligned with its vision. Are the investments that a company is making in new products and markets consistent with the stated vision?
  • Sales and Marketing
    This is a measure of the effectiveness of a company’s sales and marketing efforts in helping it drive demand and achieve its growth objectives.

Innovation Index

Innovation Index (II) is a measure of a company’s ability to develop products/ services/ solutions (with a clear understanding of disruptive Mega Trends) that are globally applicable, are able to evolve and expand to serve multiple markets and are aligned to customers’ changing needs.

  • INNOVATION SCALABILITY
    This determines whether an organization’s innovations are globally scalable and applicable in both developing and mature markets, and also in adjacent and non-adjacent industry verticals.
  • RESEARCH AND DEVELOPMENT
    This is a measure of the efficacy of a company’s R&D strategy, as determined by the size of its R&D investment and how it feeds the innovation pipeline.
  • PRODUCT PORTFOLIO
    This is a measure of a company’s product portfolio, focusing on the relative contribution of new products to its annual revenue.
  • MEGATRENDS LEVERAGE
    This is an assessment of a company’s proactive leverage of evolving, long-term opportunities and new business models, as the foundation of its innovation pipeline.
  • CUSTOMER ALIGNMENT
    This evaluates the applicability of a company’s products/services/solutions to current and potential customers, as well as how its innovation strategy is influenced by evolving customer needs.

Significance of Being on the Frost Radar™

Companies plotted on the Frost RadarTM are the leaders in the industry for growth, innovation, or both. They are instrumental in advancing the industry into the future.

  • GROWTH POTENTIAL
    Your organization has significant future growth potential, which makes it a Company to Action.
  • BEST PRACTICES
    Your organization is well positioned to shape Growth Pipeline™ best practices in your industry.
  • COMPETITIVE INTENSITY
    Your organization is one of the key drivers of competitive intensity in the growth environment.
  • CUSTOMER VALUE
    Your organization has demonstrated the ability to significantly enhance its customer value proposition.
  • PARTNER POTENTIAL
    Your organization is top of mind for customers, investors, value chain partners, and future talent as a significant value provider.

Have questions about this research or need deeper insights?
Speak directly with our analytics experts for tailored recommendations.

Recent related Life Sciences research

13 Jan 2025   |   Global   |   Market Outlook

Top 6 Growth Opportunities for the Digital Health Industry, 2025

Driven by digital advancements, the healthcare industry is transforming rapidly. Current trends and challenges create constant change, and industry stakeholders must adapt to remain attractive, competitive, and unique as robust organizations. Each year, competitors must gain a fresh, comprehensive v...

17 Dec 2024   |   Global   |   Market Research

Cybersecurity in Healthcare, United States, 2024

Healthcare is the industry most affected by cyberattacks, which have targets like hospitals, healthcare organizations, patient databases, and connected devices. These attacks not only destabilize healthcare systems but also threaten care delivery and patient safety. The global healthcare infrastruct...

12 Dec 2024   |   Global   |   Market Outlook

Top 6 Growth Opportunities for Clinical Diagnostics, Global, 2025

Accounting for 2%-3% of total healthcare expenditure and influencing 70% of clinical decision-making, diagnostics is the silent champion supporting all stages of precision health, including risk stratification, screening, early diagnosis, prognosis, monitoring, and relapse. The discovery and trans...

05 Dec 2024   |   Global   |   Frost Radar

Frost Radar™: Enterprise Conversational AI in Healthcare, 2024

This Frost Radar™ benchmarks the companies and their solutions that allow healthcare payers and providers to create next-generation virtual assistants. Conversational AI is primarily used to streamline patient and provider processes and interactions across the care continuum—the pre-care, at-care, a...

27 Nov 2024   |   Global   |   Market Research

Generative AI in Payer and Provider IT Transformation, Global, 2024-2029

The healthcare payer and provider industry is gradually adopting generative artificial intelligence (Gen AI) solutions across its value chain. Almost all organizations have shown an intent to implement Gen AI-based solutions in their products or processes, with a few already embarking on this journe...

 

Purchase includes:
  • Report download
  • Growth Dialog™ with our experts

Growth Dialog™

A tailored session with you where we identify the:
  • Strategic Imperatives
  • Growth Opportunities
  • Best Practices
  • Companies to Action

Impacting your company's future growth potential.

The immunoassay and clinical chemistry market is the highest share contributor for the total in vitro diagnostics (IVD) market. Globally valued at $28.7 billion in 2019, this market segment contributes 37.6% of the total IVD market of $76.3 billion. Within the high-medium to low analyzer segment, there are over 40 companies globally. Of these, 14 companies are benchmarked in this study. Point of care testing is not included in this study. The market concentration is relatively high amidst the Tier I companies, which includes Siemens Healthineers, Roche Diagnostics, Abbott Diagnostics, Beckman Coulter, and Ortho Clinical Diagnostics. Some evolving trends include an interest in small scale analyzers and niche/specialty reagents. There is also a need to establish references that generate a push to single-vendor system across a healthcare system. There is heavy focus on automation to address sample management, especially in pediatric hospitals, and there is an interest in adding third-party niche assays to existing platforms. Finally, there is a need for constant research and development (R&D) innovation to add a new pipeline of assays in areas such as brain injury, hs- troponin (particularly in the United States), sepsis, and other potential applications of PCT, ischemic stroke, and kidney disease. The report provides global market share, market size, and brand penetration and pricing/discounts on popular vendors and models from FY 2018 to FY 2019. The companies that are profiled in this report include Roche Diagnostics, Siemens Healthineers, Abbott Diagnostics, Beckman Coulter (Danaher), Ortho Clinical Diagnostics, Bio-Rad, Thermo Fisher Scientific, bioMerieux, Fujirebio, Sekisui Diagnostics, MindRay, Randox, and Sysmex. The report provides a summary of the strengths, opportunity areas, and position of these companies on the Frost Radar across the growth index and innovation index. Particular R&D activities and installed bases on analyzers and strategic expansion plans have been noted. The Frost Radar reveals the market positioning of companies in an industry using their Growth and Innovation scores as highlighted in the Frost Radar methodology. The document presents competitive profiles on each of the companies in the Frost Radar based on their strengths, opportunities, and a small discussion on their positioning. Frost & Sullivan analyzes hundreds of companies in the industry and benchmarks them across 10 criteria on the Frost Radar, where the leading companies in the industry are then positioned. Industry leaders on both the Growth and Innovation indices are recognized as best practice recipients. Author: Divyaa Ravishankar
More Information
Deliverable Type Frost Radar
No Index No
Podcast No
Author Divyaa Ravishankar
Industries Healthcare
WIP Number K3F6-01-00-00-00
Is Prebook No
GPS Codes 9600-B1,9825-B1,9562-B1,9571-B1,9573-B1,99C1-B1,99C6-B1,99C9-B1,99CB-B1,9568-B1,9611-B1,9627-B1

Frost Radar in the Immunoassay and Clinical Chemistry Market

$4,950.00

Special Price $3,712.50 save 25 %

In stock
SKU
HC03215-GL-MR_23585